Juan Andres - 17 Dec 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
17 Dec 2021
Transactions value $
-$5,928,650
Form type
4
Filing time
21 Dec 2021, 15:06:10 UTC
Previous filing
17 Dec 2021
Next filing
23 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61.1K +5K $12.21* 5K 17 Dec 2021 Direct F1
transaction MRNA Common Stock Sale -$1.38M -5K -100% $275.68 0 17 Dec 2021 Direct F1
transaction MRNA Common Stock Options Exercise $142K +10K $14.22* 10K 20 Dec 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61.1K +5K +50% $12.21* 15K 20 Dec 2021 Direct F1
transaction MRNA Common Stock Sale -$4.81M -15K -100% $320.97 0 20 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -14.29% $0.00 30K 17 Dec 2021 Common Stock 5K $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10K -25.89% $0.00 28.6K 20 Dec 2021 Common Stock 10K $14.22 Direct F1, F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5K -16.67% $0.00 25K 20 Dec 2021 Common Stock 5K $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 This option is fully vested and exercisable.
F3 25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer